BACKGROUND: Studies suggest that testing for individual human papillomavirus (HPV) genotypes can improve risk stratification in women with minor cytologic abnormalities. We evaluated genotyping for HPV16, HPV16/18, and HPV16/18/45 in carcinogenic HPV-positive women with atypical squamous cells of undetermined significance (ASCUS) and low-grade squamous intraepithelial lesion (LSIL) cytology. METHODS:For women enrolled in the ASCUS-LSIL Triage Study (ALTS), we calculated the age-stratified (<30 and 30+ years) positivity and cumulative risk over two years of cervical intraepithelial neoplasia grade 3 or worse (CIN3+) when testing positive or negative for three genotype combinations: HPV16, HPV16/18, and HPV16/18/45. RESULTS: Among women with ASCUS cytology, HPV16 positivity was 17.1% and increased to 22.0% (P < 0.001) for HPV16/18 and 25.6% (P < 0.001) for HPV16/18/45. Among women with LSIL cytology, HPV16 positivity was 21.1% and increased to 30.0% (P < 0.001) for HPV16/18 and 34.0% (P = 0.017) for HPV16/18/45. Regardless of cytology and age group, the greatest risk difference between test positives and test negatives was observed for HPV16 with decreasing risk stratification for HPV16/18 and HPV16/18/45. However, testing negative for any of the three combinations while being positive for another carcinogenic type still implied a two-year risk of CIN3+ of 7.8% or more. CONCLUSIONS: Although genotyping for HPV16, 18, and 45 provided additional risk stratification in carcinogenic HPV-positive women with minor cytologic abnormalities, the risk among genotype-negative women was still high enough to warrant immediate colposcopy referral. IMPACT: HPV genotyping in HPV-positive women with minor cytologic abnormalities will likely not alter clinical management. Adding HPV45 to genotyping assays is not warranted.
RCT Entities:
BACKGROUND: Studies suggest that testing for individual human papillomavirus (HPV) genotypes can improve risk stratification in women with minor cytologic abnormalities. We evaluated genotyping for HPV16, HPV16/18, and HPV16/18/45 in carcinogenic HPV-positivewomen with atypical squamous cells of undetermined significance (ASCUS) and low-grade squamous intraepithelial lesion (LSIL) cytology. METHODS: For women enrolled in the ASCUS-LSIL Triage Study (ALTS), we calculated the age-stratified (<30 and 30+ years) positivity and cumulative risk over two years of cervical intraepithelial neoplasia grade 3 or worse (CIN3+) when testing positive or negative for three genotype combinations: HPV16, HPV16/18, and HPV16/18/45. RESULTS: Among women with ASCUS cytology, HPV16 positivity was 17.1% and increased to 22.0% (P < 0.001) for HPV16/18 and 25.6% (P < 0.001) for HPV16/18/45. Among women with LSIL cytology, HPV16 positivity was 21.1% and increased to 30.0% (P < 0.001) for HPV16/18 and 34.0% (P = 0.017) for HPV16/18/45. Regardless of cytology and age group, the greatest risk difference between test positives and test negatives was observed for HPV16 with decreasing risk stratification for HPV16/18 and HPV16/18/45. However, testing negative for any of the three combinations while being positive for another carcinogenic type still implied a two-year risk of CIN3+ of 7.8% or more. CONCLUSIONS: Although genotyping for HPV16, 18, and 45 provided additional risk stratification in carcinogenic HPV-positivewomen with minor cytologic abnormalities, the risk among genotype-negative women was still high enough to warrant immediate colposcopy referral. IMPACT: HPV genotyping in HPV-positive women with minor cytologic abnormalities will likely not alter clinical management. Adding HPV45 to genotyping assays is not warranted.
Authors: P E Gravitt; C L Peyton; T Q Alessi; C M Wheeler; F Coutlée; A Hildesheim; M H Schiffman; D R Scott; R J Apple Journal: J Clin Microbiol Date: 2000-01 Impact factor: 5.948
Authors: Thomas C Wright; Mark H Stoler; Abha Sharma; Guili Zhang; Catherine Behrens; Teresa L Wright Journal: Am J Clin Pathol Date: 2011-10 Impact factor: 2.493
Authors: Debbie Saslow; Diane Solomon; Herschel W Lawson; Maureen Killackey; Shalini L Kulasingam; Joanna Cain; Francisco A R Garcia; Ann T Moriarty; Alan G Waxman; David C Wilbur; Nicolas Wentzensen; Levi S Downs; Mark Spitzer; Anna-Barbara Moscicki; Eduardo L Franco; Mark H Stoler; Mark Schiffman; Philip E Castle; Evan R Myers Journal: CA Cancer J Clin Date: 2012-03-14 Impact factor: 508.702
Authors: Mark H Einstein; Mark G Martens; Francisco A R Garcia; Daron G Ferris; Amy L Mitchell; Stephen P Day; Marilyn C Olson Journal: Gynecol Oncol Date: 2010-05-21 Impact factor: 5.482
Authors: Mark H Einstein; Francisco A R Garcia; Amy L Mitchell; Stephen P Day Journal: Cancer Epidemiol Biomarkers Prev Date: 2011-04-28 Impact factor: 4.254
Authors: Mark Schiffman; Laurence M Vaughan; Tina R Raine-Bennett; Philip E Castle; Hormuzd A Katki; Julia C Gage; Barbara Fetterman; Brian Befano; Nicolas Wentzensen Journal: Gynecol Oncol Date: 2015-07-04 Impact factor: 5.482
Authors: Eliane Rohner; Claire Edelman; Busola Sanusi; John W Schmitt; Anna Baker; Kirsty Chesko; Brian Faherty; Sean M Gregory; LaHoma S Romocki; Vijay Sivaraman; Julie A E Nelson; Siobhan O'Connor; Michael G Hudgens; Andrea K Knittel; Lisa Rahangdale; Jennifer S Smith Journal: Cancer Epidemiol Biomarkers Prev Date: 2020-09-17 Impact factor: 4.254
Authors: Maria Demarco; Noorie Hyun; Olivia Carter-Pokras; Tina R Raine-Bennett; Li Cheung; Xiaojian Chen; Anne Hammer; Nicole Campos; Walter Kinney; Julia C Gage; Brian Befano; Rebecca B Perkins; Xin He; Cher Dallal; Jie Chen; Nancy Poitras; Marie-Helene Mayrand; Francois Coutlee; Robert D Burk; Thomas Lorey; Philip E Castle; Nicolas Wentzensen; Mark Schiffman Journal: EClinicalMedicine Date: 2020-04-25
Authors: Maria Demarco; Didem Egemen; Tina R Raine-Bennett; Li C Cheung; Brian Befano; Nancy E Poitras; Thomas S Lorey; Xiaojian Chen; Julia C Gage; Philip E Castle; Nicolas Wentzensen; Rebecca B Perkins; Richard S Guido; Mark Schiffman Journal: J Low Genit Tract Dis Date: 2020-04 Impact factor: 3.842